Skip to Content

Kevzara Approval History

  • FDA approved: Yes (First approved May 22nd, 2017)
  • Brand name: Kevzara
  • Generic name: sarilumab
  • Dosage form: Injection
  • Company: Sanofi and Regeneron Pharmaceuticals, Inc.
  • Treatment for: Rheumatoid Arthritis

Kevzara (sarilumab) is an interleukin-6 receptor (IL-6R) antibody for the treatment of adults with rheumatoid arthritis.

Development History and FDA Approval Process for Kevzara

DateArticle
May 22, 2017Approval Sanofi and Regeneron Announce FDA Approval of Kevzara (sarilumab) for Rheumatoid Arthritis
Apr 28, 2017Sanofi and Regeneron Announce Kevzara (sarilumab) Biologics License Application Resubmission Accepted for Review by US FDA
Oct 28, 2016Sanofi and Regeneron Receive Complete Response Letter from FDA for Sarilumab, an Investigational Treatment for Rheumatoid Arthritis
Mar 11, 2016Sanofi and Regeneron Announce Topline Results of Phase 3 Monotherapy Study Demonstrating Superiority of Sarilumab Vs. Adalimumab in Patients with Active Rheumatoid Arthritis
Jan  8, 2016Sanofi and Regeneron Announce Sarilumab BLA Accepted for Review by FDA
Nov  8, 2015Sanofi and Regeneron Present Results From Pivotal Phase 3 Study of Sarilumab at American College of Rheumatology Annual Meeting
May 21, 2015Sanofi And Regeneron Announce Positive Topline Results From Phase 3 Studies With Sarilumab In Rheumatoid Arthritis

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide